GAMMA Investing LLC Buys 110 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

GAMMA Investing LLC grew its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 17.9% in the second quarter, HoldingsChannel reports. The fund owned 726 shares of the biopharmaceutical company’s stock after acquiring an additional 110 shares during the period. GAMMA Investing LLC’s holdings in Alnylam Pharmaceuticals were worth $237,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Bayforest Capital Ltd raised its stake in shares of Alnylam Pharmaceuticals by 14.6% during the first quarter. Bayforest Capital Ltd now owns 306 shares of the biopharmaceutical company’s stock worth $83,000 after buying an additional 39 shares during the last quarter. Fulton Bank N.A. boosted its position in Alnylam Pharmaceuticals by 3.3% during the second quarter. Fulton Bank N.A. now owns 1,421 shares of the biopharmaceutical company’s stock worth $463,000 after purchasing an additional 46 shares during the period. Northwestern Mutual Wealth Management Co. raised its position in shares of Alnylam Pharmaceuticals by 10.3% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 525 shares of the biopharmaceutical company’s stock valued at $142,000 after purchasing an additional 49 shares during the period. Edmond DE Rothschild Holding S.A. increased its position in Alnylam Pharmaceuticals by 18.2% during the first quarter. Edmond DE Rothschild Holding S.A. now owns 318 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 49 shares during the period. Finally, Lindbrook Capital LLC increased its position in Alnylam Pharmaceuticals by 9.2% during the first quarter. Lindbrook Capital LLC now owns 596 shares of the biopharmaceutical company’s stock worth $161,000 after acquiring an additional 50 shares during the period. 92.97% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, Director Colleen F. Reitan sold 18,000 shares of the stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $467.60, for a total transaction of $8,416,800.00. Following the transaction, the director directly owned 775 shares in the company, valued at $362,390. This trade represents a 95.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Michael W. Bonney sold 11,250 shares of the stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $450.00, for a total value of $5,062,500.00. Following the sale, the director directly owned 16,804 shares of the company’s stock, valued at approximately $7,561,800. This trade represents a 40.10% decrease in their position. The disclosure for this sale can be found here. Insiders sold 75,594 shares of company stock valued at $33,968,256 in the last 90 days. 1.50% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ALNY. HC Wainwright restated a “buy” rating and issued a $570.00 price target on shares of Alnylam Pharmaceuticals in a research note on Tuesday, September 2nd. The Goldman Sachs Group lifted their target price on shares of Alnylam Pharmaceuticals from $504.00 to $566.00 and gave the stock a “buy” rating in a research note on Tuesday, September 16th. UBS Group lifted their price objective on shares of Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the company a “buy” rating in a research note on Friday, August 1st. Truist Financial initiated coverage on shares of Alnylam Pharmaceuticals in a research note on Monday, July 21st. They issued a “buy” rating and a $385.00 price objective for the company. Finally, Wall Street Zen lowered shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 5th. Twenty-four analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $439.58.

Alnylam Pharmaceuticals Price Performance

ALNY opened at $446.40 on Friday. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75. The company has a market capitalization of $58.51 billion, a price-to-earnings ratio of -180.73 and a beta of 0.32. The firm’s fifty day moving average price is $428.51 and its two-hundred day moving average price is $332.08. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $484.21.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The business had revenue of $773.69 million for the quarter, compared to analysts’ expectations of $633.54 million. During the same period in the previous year, the business posted ($0.13) EPS. The firm’s quarterly revenue was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.